PI

Curadev's Differentiated Next Generation STING Agonist CRD3874-SI

Retrieved on: 
Thursday, February 15, 2024

BOSTON and NOIDA, India, Feb. 15, 2024 /PRNewswire/ -- Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site.

Key Points: 
  • BOSTON and NOIDA, India, Feb. 15, 2024 /PRNewswire/ -- Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site.
  • An intravenous formulation of this lead asset (CRD3874-SI) recently received approval from the US FDA for use in first-in-human studies in patients with advanced solid cancers.
  • These features of CRD3874-SI predict a high therapeutic index in humans and support clinical investigation of this agent in cancer patients.
  • The poster was co-authored by Dr. Ciara Kelly , MD, Memorial Sloan Kettering Cancer Center, who is the PI for the FIH study ( NCT06021626 ).

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Retrieved on: 
Wednesday, February 14, 2024

“Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”

Key Points: 
  • “Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
    GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies.
  • Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases.
  • His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease.
  • He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

How Supply & Demand is Likely Driving the Uranium Market to Reach a 16-Year Peak This Year

Retrieved on: 
Wednesday, February 14, 2024

PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Experts predict that the global uranium market is likely to reach a 16 year peak in 2024.

Key Points: 
  • PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Experts predict that the global uranium market is likely to reach a 16 year peak in 2024.
  • Toronto-listed Cameco is expected to be the world's second largest uranium producer this year after Kazatomprom.
  • The objective of the 2024 program is the discovery of uranium mineralization associated with conductive electromagnetic (EM) anomalies.
  • “We are incredibly excited to be starting the preparations for our maiden drill program, a key milestone for the company.

Pender Growth Fund Provides Notice of its Intention to Undertake Normal Course Issuer Bid

Retrieved on: 
Tuesday, February 13, 2024

VANCOUVER, British Columbia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- (TSXV: PTF) Pender Growth Fund Inc. (the “Company”) announces that it has provided the TSX Venture Exchange (the "TSXV") with its Notice of Intention to make a Normal Course Issuer Bid (the "NCIB") through the facilities of the TSXV, subject to TSXV acceptance.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- (TSXV: PTF) Pender Growth Fund Inc. (the “Company”) announces that it has provided the TSX Venture Exchange (the "TSXV") with its Notice of Intention to make a Normal Course Issuer Bid (the "NCIB") through the facilities of the TSXV, subject to TSXV acceptance.
  • As of January 30, 2024, the Company had 7,362,121 Shares outstanding, of which 6,301,883 Shares represent the Company's public float.
  • The prices that the Company will pay for Shares purchased will be the market price of the Shares at the time of purchase.
  • The Company reserves the right to terminate the NCIB earlier if it feels it is appropriate to do so.

Avante Launches Homeworxx Providing Trusted, Vetted, and Security Background Checked Trades for Luxury Homes and Toyboxx for Vehicle Storage Security Solutions; Announces Engagement of Investor Relations Consultant

Retrieved on: 
Friday, February 9, 2024

Avante’s vetted and trusted home managers are well-connected and have a vast network to accommodate anything clients may have in mind.

Key Points: 
  • Avante’s vetted and trusted home managers are well-connected and have a vast network to accommodate anything clients may have in mind.
  • Avante Toyboxx is a premier auto storage service tailored for automotive enthusiasts, collectors, and owners of high-value vehicles.
  • Available in Toronto, Ontario, the service is intended to redefine vehicle storage by delivering unmatched security, climate-controlled preservation, and ultimate peace of mind.
  • Furthermore, the Toyboxx storage service is also flexible for Avante clients, providing options for short-term storage while clients are away on vacation, in addition to longer-term seasonal storage.

MedBright AI Announces Closing of LIFE Offering for Gross Proceeds of Approximately $1.4 Million

Retrieved on: 
Friday, February 9, 2024

Pursuant to the Offering, a total of 6,994,887 Units were sold at a price per Unit of $0.20 (the “Offering Price”).

Key Points: 
  • Pursuant to the Offering, a total of 6,994,887 Units were sold at a price per Unit of $0.20 (the “Offering Price”).
  • Each Unit consists of one common share of the Company (a “Share”) and one-half of one Share purchase warrant (each whole warrant, a “Warrant”).
  • The Offering has been conducted pursuant to the listed issuer financing exemption from prospectus requirements in Part 5A of National Instrument 45-106 – Prospectus Exemptions ("NI 45-106").
  • The Units, the Warrants and the Warrant Shares are not subject to resale restrictions pursuant to applicable Canadian securities laws.

IsoEnergy Completes C$23 Million Bought Deal Private Placement

Retrieved on: 
Friday, February 9, 2024

IsoEnergy is also pleased to announce that it has engaged Momentum IR Corp. ("Momentum"), a Toronto-based investor relations and corporate communications firm.

Key Points: 
  • IsoEnergy is also pleased to announce that it has engaged Momentum IR Corp. ("Momentum"), a Toronto-based investor relations and corporate communications firm.
  • Momentum was previously engaged by Consolidated Uranium Inc., a wholly-owned subsidiary of the Company, and will continue to provide IsoEnergy with investor relations and advisory services.
  • Momentum is at arm's length to IsoEnergy and has no other relationship with IsoEnergy, except pursuant to the engagement.
  • The agreement and the grant of the stock options is subject to the approval of the TSX Venture Exchange.

MedRhythms Announces Key Publications Confirming Efficacy, Safety, and Usability of InTandem™ for Chronic Stroke Walking Impairment

Retrieved on: 
Thursday, February 8, 2024

Historically, there has been a key care gap in the availability of efficacious walking rehabilitation interventions for the chronic phase of stroke recovery, typically defined as six or more months after the initial stroke.

Key Points: 
  • Historically, there has been a key care gap in the availability of efficacious walking rehabilitation interventions for the chronic phase of stroke recovery, typically defined as six or more months after the initial stroke.
  • There are few interventions that can help people with chronic stroke gait impairment improve both their gait speed and quality.
  • In the randomized controlled trial, study participants with chronic stroke were randomly assigned to InTandem or an active control group.
  • These results confirm InTandem's safety and efficacy for home use by patients living with gait impairment in the chronic stroke recovery phase.

PI USA Invests in New Production Facility in MA to Support Continued Growth of High-Tech Solutions

Retrieved on: 
Wednesday, February 7, 2024

AUBURN, Mass., Feb. 7, 2024 /PRNewswire-PRWeb/ -- PI, the global leader in nanopositioning, ultra-precision motion control and piezo technology is committed to expanding its US production capacity with a new ~120,000 sqft facility in Shrewsbury, MA. The new US headquarters will be three times the aggregated space of its current locations in Auburn, MA, Hopkinton, MA, and Nashua, NH. Beginning in 2025, PI will manufacture precision motion and automation systems, air bearings and piezoelectric transducers and nanopositioning components for leading edge applications in industry and research at this new facility, while also driving the development of innovative technologies.

Key Points: 
  • Awarding the contract for a new on-shore production facility is another step in The PI Group's multi-year growth plan.
  • The new US headquarters will be three times the aggregated space of its current locations in Auburn, MA, Hopkinton, MA, and Nashua, NH.
  • "Over the past five years, annual sales of PI USA have grown by more than 10 percent.
  • "With this new production facility, we lay the foundation to meet the growing demands of the American markets.

CIRO Sanctions Donald Warren Metcalfe

Retrieved on: 
Tuesday, February 6, 2024

VANCOUVER, BC, Feb. 6, 2024 /CNW/ - Following a penalty hearing held on January 30, 2024 pursuant to the Investment Dealer and Partially Consolidated Rules, a hearing panel of the Canadian Investment Regulatory Organization (CIRO) imposed the following sanctions on Donald Warren Metcalfe:

Key Points: 
  • VANCOUVER, BC, Feb. 6, 2024 /CNW/ - Following a penalty hearing held on January 30, 2024 pursuant to the Investment Dealer and Partially Consolidated Rules, a hearing panel of the Canadian Investment Regulatory Organization (CIRO) imposed the following sanctions on Donald Warren Metcalfe:
    a permanent bar to approval in any capacity.
  • Donald Warren Metcalfe is also required to pay costs in the amount of $68,908.
  • The violations occurred while Donald Warren Metcalfe was the President and Chief Operating Officer of Chippingham Financial Group Limited and later the Executive Vice Chairman and a Director of PI Financial Corp.
  • CIRO is committed to the protection of investors, providing efficient and consistent regulation, and building Canadians' trust in financial regulation and the people managing their investments.